Supplementary Table 3A. Liver-related Events distribution (splitting for HCC) in MASLD patients during 5-year follow-up: detailed reporting (Training Cohort)

Number of events (Total): 77 **First LREs: 59** **HCC occurrence: 18**		**Frequency distribution according to baseline liver fibrosis stage (N. of patients)**		**Chi-square test (F0F2 vs F3F4)**
Hepatocellular carcinoma occurence	18	**F0-F2 (n:85)**	8	**p<0.0001**
		F3-F4 (n:103)	10	
Ascites	37	**F0-F2 (n:85)**	6	**p<0.0001**
		F3-F4 (n:103)	31	
Hepatic encephalopathy	14	**F0-F2 (n:85)**	2	**p<0.0001**
		F3-F4 (n:103)	12	
Gastroesophageal bleeding	4	**F0-F2 (n:85)**	0	/
		F3-F4 (n:103)	4	
Jaundice	4	**F0-F2 (n:85)**	0	/
		F3-F4 (n:103)	4	

12 individuals were lost (5 F0-F2 and 7 F3-F3 individuals dead of extrahepatic and extra-cardiovascular events). *HCC: Hepatocellular carcinoma; CSPH: Clinically Significant portal hypertension FUP: follow-up;*Chi-square test. Statistically significant differences (p<0.05) are reported in bold; n.s: not statistically significant.*

Supplementary table 3B. Liver-related Events distribution (splitting for HCC) during 5-year follow-up: detailed reporting (Validation Cohort)

Number of events (Total): 28 **First LREs: 19** **HCC occurrence: 9**		**Frequency distribution according to baseline liver fibrosis stage (Number of patients)**		**Chi-square test (F0F2 vs F3F4)**
Hepatocellular carcinoma occurence	9	**F0-F2 (n:27)**	1	**p<0.0001**
		F3-F4 (n:33)	8	
Ascites	8	**F0-F2 (n:27)**	1	**p<0.0001**
		F3-F4 (n:33)	7	
Hepatic encephalopathy	5	**F0-F2 (n:27)**	1	**p<0.0001**
		F3-F4 (n:33)	4	
Gastroesophageal bleeding	3	**F0-F2 (n:27)**	0	/
		F3-F4 (n:33)	3	
Jaundice	3	**F0-F2 (n:27)**	0	/
		F3-F4 (n:33)	3	

*HCC: Hepatocellular carcinoma. *Chi-square test. Statistically significant differences (p<0.05) are reported in bold; n.s: not statistically significant*